This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2007 Dec;178(6):2314-30.

doi: 10.1016/j.juro.2007.09.003.

Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update

M Craig Hall¹, Sam S Chang, Guido Dalbagni, Raj Som Pruthi, John Derek Seigne, Eila Curlee Skinner, J Stuart Wolf Jr, Paul F Schellhammer

Affiliations

PMID: 17993339
DOI: 10.1016/j.juro.2007.09.003

Review

Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update

M Craig Hall et al. J Urol. 2007 Dec.

. 2007 Dec;178(6):2314-30.

doi: 10.1016/j.juro.2007.09.003.

Authors

M Craig Hall¹, Sam S Chang, Guido Dalbagni, Raj Som Pruthi, John Derek Seigne, Eila Curlee Skinner, J Stuart Wolf Jr, Paul F Schellhammer

Affiliation

¹ American Urological Association Education and Research, Inc., USA. Craig.Hall@cornerstonehealthcare.com

PMID: 17993339
DOI: 10.1016/j.juro.2007.09.003

No abstract available

PubMed Disclaimer

Comment in

Bladder cancer: Defining intermediate-risk non-muscle-invasive bladder cancer.
Malkowicz SB. Malkowicz SB. Nat Rev Urol. 2014 Aug;11(8):430-2. doi: 10.1038/nrurol.2014.172. Epub 2014 Jul 22. Nat Rev Urol. 2014. PMID: 25048864 No abstract available.

Similar articles

Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E, Fujimoto H, Mizutani Y, Okajima E, Koga H, Hinotsu S, Shinohara N, Oya M, Miki T; Cancer Registration Committee of the Japanese Urological Association. Kikuchi E, et al. Int J Urol. 2009 Mar;16(3):279-86. doi: 10.1111/j.1442-2042.2008.02235.x. Epub 2009 Jan 20. Int J Urol. 2009. PMID: 19207609
Clinical outcome of high-grade non-muscle-invasive bladder cancer: a long-term single center experience.
Iida S, Kondo T, Kobayashi H, Hashimoto Y, Goya N, Tanabe K. Iida S, et al. Int J Urol. 2009 Mar;16(3):287-92. doi: 10.1111/j.1442-2042.2008.02239.x. Epub 2009 Feb 4. Int J Urol. 2009. PMID: 19207115
Current problems and needs in the treatment of pT1 G3 bladder carcinoma.
Martínez Portillo FJ, Alken P. Martínez Portillo FJ, et al. Int Urol Nephrol. 2002;33(1):29-40. doi: 10.1023/a:1014492517088. Int Urol Nephrol. 2002. PMID: 12090335 Review. No abstract available.
The case for neoadjuvant chemotherapy and cystectomy for muscle invasive bladder cancer.
deVere White RW, Katz MH, Steinberg GD. deVere White RW, et al. J Urol. 2009 May;181(5):1994-7. doi: 10.1016/j.juro.2009.02.052. Epub 2009 Mar 14. J Urol. 2009. PMID: 19286209 Review. No abstract available.
Contemporary management of stage T1 transitional cell carcinoma of the bladder.
Sataa S, Yassine N, Ghassen HH, Imed BS, Mohamed C, Maher C, Ali H. Sataa S, et al. Tunis Med. 2005 Dec;83 Suppl 12:87-9. Tunis Med. 2005. PMID: 16430077 Review. No abstract available.

See all similar articles

Cited by

Intravesical Gemcitabine and Docetaxel Therapy for BCG-Naïve Patients: A Promising Approach to Non-Muscle Invasive Bladder Cancer.
Bakula M, Hudolin T, Knezevic N, Zimak Z, Andelic J, Juric I, Gamulin M, Gnjidic M, Kastelan Z. Bakula M, et al. Life (Basel). 2024 Jun 22;14(7):789. doi: 10.3390/life14070789. Life (Basel). 2024. PMID: 39063544 Free PMC article.
Sensitivity and Specificity in Urine Bladder Cancer Markers - Is it that Simple?
Roghmann F, Goebell PJ, Dyrskjøt L, van Rhijn BWG, Käfferlein HU, Hakenberg O, Stenzl A, Burger M, Pesch B, Benderska-Söder N, Schmitz-Dräger BJ. Roghmann F, et al. Bladder Cancer. 2022 Mar 11;8(1):1-4. doi: 10.3233/BLC-211602. eCollection 2022. Bladder Cancer. 2022. PMID: 38994515 Free PMC article.
Prevalence of Bladder Cancers Incidentally Detected During Multiparametric MRI Scans of the Prostate Gland and the Clinical Significance of Scoring Them According to VI-RADS: A Pictorial Single-Centre Study.
Onder RO, Aslan S, Bekci T. Onder RO, et al. J Belg Soc Radiol. 2024 Feb 1;108(1):7. doi: 10.5334/jbsr.3318. eCollection 2024. J Belg Soc Radiol. 2024. PMID: 38312149 Free PMC article.
The 15-year national trends of urinary cancers incidence among Iranian men and women; 2005-2020.
Mousavian AH, Shafiee G, Sheidaei A, Balajam NZ, Ebrahimi M, Khatami F, Gohari K, Aryan A, Ghanbari-Motlagh A, Ostovar A, Aghamir SMK, Heshmat R. Mousavian AH, et al. Int J Equity Health. 2024 Jan 22;23(1):13. doi: 10.1186/s12939-023-02084-1. Int J Equity Health. 2024. PMID: 38254127 Free PMC article.
Results Obtained from a Pivotal Validation Trial of a Microsatellite Analysis (MSA) Assay for Bladder Cancer Detection through a Statistical Approach Using a Four-Stage Pipeline of Modern Machine Learning Techniques.
Reynolds T, Riddick G, Meyers G, Gordon M, Flores Monar GV, Moon D, Moon C. Reynolds T, et al. Int J Mol Sci. 2023 Dec 29;25(1):472. doi: 10.3390/ijms25010472. Int J Mol Sci. 2023. PMID: 38203643 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information